pharma · Waldenstrom Macroglobulinemia · Non Small Cell Lung Cancer · CLRB
Cellectar Biosciences
Cellectar Biosciences is a pharma organization headquartered in Florham Park, USA. It trades on NYSE under ticker CLRB. Primary therapeutic focus areas include Waldenstrom Macroglobulinemia, Non Small Cell Lung Cancer, B
100 Campus Dr, 207, Florham Park, New Jersey 07932, US HQ
21 Employees
Public company Type
CLRB · NYSE Ticker
Company details
- Status
- Public
- HQ
- 100 Campus Dr, 207, Florham Park, New Jersey 07932, US
- Employees
- 21
- Programs
- 17
- Drugs
- 7
- Patents
- 7
Iopofosine I 131 single dose
Phase 2 · small molecule · Waldenstrom Macroglobulinemia
Iopofosine I 131 single dose for Waldenstrom Macroglobulinemia is a Phase 2 program (small_molecule) at Cellectar Biosciences with 1 ClinicalTrials.gov record(s).
Internal code DCL-16-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Cellectar Biosciences
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Waldenstrom Macroglobulinemia
- Status
- active
- Trials
- 1